Evidence map›Paper›PMID 36670634›Full record

ReviewChildren (Basel, Switzerland)2022

The Entity of Cerebellar Mutism Syndrome: A Narrative Review Centered on the Etiology, Diagnostics, Prevention, and Therapeutic Options.

Dimitrios Panagopoulos, Georgios Stranjalis, Maria Gavra, Efstathios Boviatsis, Stefanos Korfias, Ploutarchos Karydakis, Marios Themistocleous

Open access · goldAbstract readReview
In one paragraph

Review in Children (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Dimitrios PanagopoulosNeurosurgical Department, Pediatric Hospital of Athens, 'Agia Sophia', 45701 Athens, Greece.ORCID 0000-0002-7918-5065
Georgios Stranjalis1st University Neurosurgical Department, 'Evangelismos' Hospital, University of Athens, Neurosurgery, Medical School, 10676 Athens, Greece.
Maria GavraRadiology Department, Pediatric Hospital of Athens, 'Agia Sophia', 45701 Athens, Greece.
Efstathios Boviatsis2nd University Neurosurgical Department, 'Attikon' Hospital, University of Athens, Neurosurgery, Medical School, 12462 Athens, Greece.
Stefanos Korfias1st University Neurosurgical Department, 'Evangelismos' Hospital, University of Athens, Neurosurgery, Medical School, 10676 Athens, Greece.
Ploutarchos KarydakisNeurosurgical Department, General Hospital of Athens 'Gennimatas', 11527 Athens, Greece.
Marios ThemistocleousNeurosurgical Department, Pediatric Hospital of Athens, 'Agia Sophia', 45701 Athens, Greece.
Children's Hospital Agia Sophia · GRNational and Kapodistrian University of Athens · GRGeneral Hospital of Athens G. Genimatas · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebellar mutism syndrome (CMS), also known as posterior fossa syndrome, is an entity that entails a constellation of signs and symptoms which are recorded in a limited number of pediatric patients who have been operated on mainly for tumors involving the posterior cranial fossa, and more precisely, the region of the vermis. Medulloblastoma seems to constitute the most commonly recognized pathological substrate, associated with this entity. The most prevalent constituents of this syndrome are noted to be a, often transient, although protracted, language impairment, emotional lability, along with cerebellar and brainstem dysfunction. Apart from that, a definite proportion of involved individuals are affected by irreversible neurological defects and long-lasting neurocognitive impairment. A bulk of literature and evidence based on clinical trials exist, which reflect the continuous effort of the scientific community to highlight all perspectives of this complex phenomenon. There are several circumstances that intervene in our effort to delineate the divergent parameters that constitute the spectrum of this syndrome. In summary, this is implicated by the fact that inconsistent nomenclature, poorly defined diagnostic criteria, and uncertainty regarding risk factors and etiology are all constituents of a non-well-investigated syndrome. Currently, a preliminary consensus exists about the identification of a group of diagnostic prerequisites that are managed as sine qua non, in our aim to document the diagnosis of CMS. These include language impairment and emotional lability, as proposed by the international Board of the Posterior Fossa Society in their consensus statement. It is common concept that midline tumor location, diagnosis of medulloblastoma, younger age at diagnosis, and preoperatively established language impairment should be accepted as the most determinant predisposing conditions for the establishment of this syndrome. A well-recognized pathophysiological explanation of CMS includes disruption of the cerebellar outflow tracts, the cerebellar nuclei, and their efferent projections through the superior cerebellar peduncle. Despite the relative advancement that is recorded regarding the diagnostic section of this disease, no corresponding encouraging results are reported, regarding the available treatment options. On the contrary, it is mainly targeted toward the symptomatic relief of the affected individuals. The basic tenet of our review is centered on the presentation of a report that is dedicated to the definition of CMS etiology, diagnosis, risk factors, clinical presentation, and clinical management. Apart from that, an effort is made that attempts to elucidate the paramount priorities of the scientific forum, which are directed toward the expansion our knowledge in the era of diagnostics, prevention, and therapeutic options for patients suffering from CM, or who are at risk for development of this syndrome.

Indexed as

cerebellar mutismdentate nucleusmedulloblastomaoccupational/speech therapyvermis

Identifiers

PMID36670634
PMCPMC9856273
OpenAlexW4313472847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.